InDex Pharmaceuticals discontinues cobitolimod phase III program

Index Pharmaceuticals Sweden

Independent Data Monitoring Committee (DMC) advises that cobitolimod is unlikely to meet the primary endpoint upon completion of Induction Study 1More information regarding next steps will be provided once a thorough analysis of the data from Induction Study 1 has been completedView original content:https://www.prnewswire.co.uk/news-releases/index-pharmaceuticals-discontinues-cobitolimod-phase-iii-program-301995261.html